Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Therapix Biosciences Ltd ADR TRPXY

Healthcare Biotechnology
Therapix Biosciences Ltd is a specialty clinical-stage pharmaceutical company. It is engaged in developing several innovative immunotherapy products and it owns patents in the immunotherapy field. It is focused on creating and enhancing a portfolio of technologies and assets based on cannabinoid pharmaceuticals. The operating segments of the group are Development of drugs based on cannabinoid... see more

Recent & Breaking News (OTCPK:TRPXY)

Therapix Biosciences Provides Update Regarding FSD Acquisition

PR Newswire December 11, 2018

Therapix Biosciences Reports Third Quarter 2018 Financial Results and Provides Business Update

PR Newswire December 3, 2018

Therapix Biosciences Clarifies Terms of Recently Issued Convertible Debenture

PR Newswire November 29, 2018

Therapix Biosciences Issues $1,500,000 Convertible Debenture

PR Newswire November 27, 2018

The Global Cannabis Market is Expected to Grow as More Countries Eye Legalization

PR Newswire November 5, 2018

Therapix Biosciences Signs Binding LOI to be Acquired by FSD Pharma for $48 Million, to Create Medical Cannabis Industry Innovator

PR Newswire October 24, 2018

FSD Pharma Signs Binding LOI to Acquire Therapix Biosciences, a NASDAQ Traded Pharmaceutical Company Focusing on the Development of Cannabinoid-Based Treatments, to Create Medical Cannabis Industry Innovator

Business Wire October 22, 2018

Therapix Biosciences Reports Second Quarter 2018 Financial Results and Provides Business Update

PR Newswire August 20, 2018

Therapix Biosciences Signs Term Sheet for the Transfer of Non-Pain Cannabinoid-Based Drug Pipeline Assets to Cure Pharmaceutical

PR Newswire July 12, 2018

Cure Pharmaceutical Plans to Acquire Cannabinoid-Based Drug Pipeline from Therapix Biosciences Ltd.

GlobeNewswire July 11, 2018

Legal Supply Channels are Expected to Show Big Growth in Cannabis Markets

PR Newswire June 29, 2018

Therapix Biosciences Updates Regarding TASE Delisting

PR Newswire June 27, 2018

Cannabis' Economic Impact to Expand With Emerging Markets

PR Newswire June 14, 2018

Therapix Biosciences Sponsors the 2018 Annual Meeting of the European Society for the Study of Tourette Syndrome

PR Newswire June 11, 2018

Therapix Biosciences Announces Enrollment of the First Patient for Clinical Trial at Assuta Medical Center for Treating Obstructive Sleep Apnea Using Cannabinoid-based Drug

PR Newswire June 5, 2018

Therapix Biosciences Reports First Quarter 2018 Financial Results and Provides Business Update

PR Newswire May 31, 2018

Therapix Biosciences Issues CEO's Letter to Shareholders

PR Newswire May 15, 2018

Dual-Listed Therapix to Voluntarily Delist from Tel Aviv Stock Exchange

PR Newswire May 9, 2018

Mid-Day Market Update: Dow Rises 250 Points; Menlo Therapeutics Shares Slide

Benzinga.com  April 9, 2018

Mid-Morning Market Update: Markets Open Higher; Novartis To Acquire AveXis For $8.7B

Benzinga.com  April 9, 2018